Vitamin D: Cancer and differentiation

Vitamin D

Volumn , Issue , 2011, Pages 1591-1624

  Van Leeuwen, Johannes P T M ^a   Van Driel, Marjolein ^a   Feldman, David ^b   Muñoz, Alberto ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884779788     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10083-6     Document Type: Chapter

References (473)

1. Shabahang M., Buras R.R., Davoodi F., Schumaker L.M., Nauta R.J., Evans S.R. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 1993, 53:3712-3718.
2. Buras R.R., Schumaker L.M., Davoodi F., Brenner R.V., Shabahang M., Nauta R.J., et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res. Treat. 1994, 31:191-202.
3. Villena-Heinsen C., Meyberg R., Axt-Fliedner R., Reitnauer K., Reichrath J., Friedrich M. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res. 2002, 22:2261-2267.
4. Pena C., Garcia J.M., Silva J., Garcia V., Rodriguez R., Alonso I., et al. E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum. Mol. Genet. 2005, 14:3361-3370.
5. Evans S.R., Nolla J., Hanfelt J., Shabahang M., Nauta R.J., Shchepotin I.B. Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. Clin. Cancer Res. 1998, 4:1591-1595.
6. Friedrich M., Rafi L., Tilgen W., Schmidt W., Reichrath J. Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma. J. Histochem. Cytochem. 1998, 46:1335-1337.
7. Friedrich M., Villena-Heinsen C., Tilgen W., Schmidt W., Reichrat J., Axt-Fliedner R. Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res. 2002, 22:1919-1924.
8. Eisman J.A., Suva L.J., Sher E., Pearce P.J., Funder J.W., Martin T.J. Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer. Cancer Res. 1981, 41:5121-5124.
9. Freake H.C., Abeyasekera G., Iwasaki J., Marcocci C., MacIntyre I., McClelland R.A., et al. Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res. 1984, 44:1677-1681.
10. Eisman J.A., Suva L.J., Martin T.J. Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers. Cancer Res. 1986, 46:5406-5408.
11. Berger U., Wilson P., McClelland R.A., Colston K., Haussler M.R., Pike J.W., et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res. 1987, 47:6793-6799.
12. Berger U., McClelland R.A., Wilson P., Greene G.L., Haussler M.R., Pike J.W., et al. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991, 51:239-244.
13. Goode E.L., Dunning A.M., Kuschel B., Healey C.S., Day N.E., Ponder B.A., et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 2002, 62:3052-3057.
14. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
15. Thompson P.D., Jurutka P.W., Whitfield G.K., Myskowski S.M., Eichhorst K.R., Dominguez C.E., et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Commun. 2002, 299:730-738.
16. Zinser G.M., Sundberg J.P., Welsh J., Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis Carcinogenesis 2002, 23:2103-2109.
17. Palmer H.G., Anjos-Afonso F., Carmeliet G., Takeda H., Watt F.M. The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS. One. 2008, 3:e1483.
18. Richard C.L., Farach-Carson M.C., Rohe B., Nemere I., Meckling K.A. Involvement of 1,25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp. Cell Res. 2010, 316:695-703.
19. Hoffman F.L. The Mortality of Cancer Throughout the World 1915, Prudential Press, New York.
20. Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int. J. Epidemiol. 1980, 9:227-231.
21. Garland C.F., Comstock G.W., Garland F.C., Helsing K.J., Shaw E.K., Gorham E.D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 2:1176-1178.
22. Garland C.F., Garland F.C., Gorham E.D. Can colon cancer incidence and death rates be reduced with calcium and vitamin D?. Am. J. Clin. Nutr. 1991, 54:193S-201S.
23. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B., Lipkin M., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am. J. Prev. Med. 2007, 32:210-216.
24. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. J. Natl. Cancer Inst. 2007, 99:1594-1602.
25. Garland F.C., Garland C.F., Gorham E.D., Young J.F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 1990, 19:614-622.
26. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990, 10:1307-1311.
27. Gorham E.D., Garland F.C., Garland C.F. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol. 1990, 19:820-824.
28. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70:2861-2869.
29. Ainsleigh H.G. Beneficial effects of sun exposure on cancer mortality. Prev. Med. 1993, 22:132-140.
30. Bertone-Johnson E.R., Chen W.Y., Holick M.F., Hollis B.W., Colditz G.A., Willett W.C., et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1991-1997.
31. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer. 2005, 41:1164-1169.
32. Garland C.F., Gorham E.D., Mohr S.B., Grant W.B., Giovannucci E.L., Lipkin M., et al. Vitamin D and prevention of breast cancer: pooled analysis. J. Steroid Biochem. Mol. Biol. 2007, 103:708-711.
33. Colli J.L., Grant W.B. Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. Urology 2008, 71:531-535.
34. Ahn J., Peters U., Albanes D., Purdue M.P., Abnet C.C., Chatterjee N., et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J. Natl. Cancer Inst. 2008, 100:796-804.
35. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
36. Grant W.B. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent. Results Cancer Res. 2003, 164:371-377.
37. Toriola A.T., Surcel H.M., Agborsangaya C., Grankvist K., Tuohimaa P., Toniolo P., et al. Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur. J. Cancer 2010, 46:364-369.
38. Studzinski G.P., Moore D.C. Sunlight - can it prevent as well as cause cancer?. Cancer Res. 1995, 55:4014-4022.
39. de Gruijl F.R., Longstreth J., Norval M., Cullen A.P., Slaper H., Kripke M.L., et al. Health effects from stratospheric ozone depletion and interactions with climate change. Photochem. Photobiol. Sci. 2003, 2:16-28.
40. Albert M.R., Ostheimer K.G. The evolution of current medical and popular attitudes toward ultraviolet light exposure: Part 2. J. Am. Acad. Dermatol. 2003, 48:909-918.
41. Luscombe C.J., French M.E., Liu S., Saxby M.F., Jones P.W., Fryer A.A., et al. Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001, 22:1343-1347.
42. Luscombe C.J., French M.E., Liu S., Saxby M.F., Jones P.W., Fryer A.A., et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br. J. Cancer 2001, 85:1504-1509.
43. Bodiwala D., Luscombe C.J., French M.E., Liu S., Saxby M.F., Jones P.W., et al. Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 2003, 24:711-717.
44. Jablonski N.G., Chaplin G. Skin deep. Sci. Am. 2002, 287:74-81.
45. Grant W.B., Garland C.F., Holick M.F. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem. Photobiol. 2005, 81:1276-1286.
46. Grant W.B. Solar ultraviolet irradiance and cancer incidence and mortality. Adv. Exp. Med. Biol. 2008, 624:16-30.
47. Jacobson E.A., James K.A., Newmark H.L., Carroll K.K. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 1989, 49:6300-6303.
48. Barger-Lux M.J., Heaney R.P. The role of calcium intake in preventing bone fragility, hypertension, and certain cancers. J. Nutr. 1994, 124:1406S-1411S.
49. Newmark H.L. Vitamin D adequacy: a possible relationship to breast cancer. Adv. Exp. Med. Biol. 1994, 364:109-114.
50. Kleibeuker J.H., van der M.R., de Vries E.G. Calcium and vitamin D: possible protective agents against colorectal cancer?. Eur. J. Cancer 1995, 31A:1081-1084.
51. Garland C.F., Garland F.C., Gorham E.D. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann. NY. Acad. Sci. 1999, 889:107-119.
52. McCullough M.L., Robertson A.S., Rodriguez C., Jacobs E.J., Chao A., Carolyn J., et al. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the cancer prevention study II nutrition cohort (United States). Cancer Causes Control 2003, 14:1-12.
53. Simard A., Vobecky J., Vobecky J.S. Vitamin D deficiency and cancer of the breast: an unprovocative ecological hypothesis. Can J. Public Health 1991, 82:300-303.
54. Pence B.C., Richard B.C., Lawlis R.S., Kuratko C.N. Effects of dietary calcium and vitamin D3 on tumor promotion in mouse skin. Nutr. Cancer 1991, 16:171-181.
55. Ahonen M.H., Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11:847-852.
56. Tuohimaa P., Lyakhovich A., Aksenov N., Pennanen P., Syvala H., Lou Y.R., et al. Vitamin D and prostate cancer. J. Steroid Biochem. Mol. Biol. 2001, 76:125-134.
57. La Vecchia C., Braga C., Negri E., Franceschi S., Russo A., Conti E., et al. Intake of selected micronutrients and risk of colorectal cancer. Int. J. Cancer 1997, 73:525-530.
58. Lipkin M., Reddy B., Newmark H., Lamprecht S.A. Dietary factors in human colorectal cancer. Annu. Rev. Nutr. 1999, 19:545-586.
59. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell. 2000, 6:507-515.
60. Kallay E., Pietschmann P., Toyokuni S., Bajna E., Hahn P., Mazzucco K., et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001, 22:1429-1435.
61. Miller C.W., Morosetti R., Campbell M.J., Mendoza S., Koeffler H.P. Integrity of the 1,25-dihydroxyvitamin D3 receptor in bone, lung, and other cancers. Mol. Carcinog. 1997, 19:254-257.
62. WHO 2008 Vitamin D and cancer. In: Cancer IAFRo (Ed.) Working Group Reports.
63. Taylor J.A., Hirvonen A., Watson M., Pittman G., Mohler J.L., Bell D.A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996, 56:4108-4110.
64. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 1997, 89:166-170.
65. Ingles S.A., Coetzee G.A., Ross R.K., Henderson B.E., Kolonel L.N., Crocitto L., et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 1998, 58:1620-1623.
66. Correa-Cerro L., Berthon P., Haussler J., Bochum S., Drelon E., Mangin P., et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum. Genet. 1999, 105:281-287.
67. Habuchi T., Suzuki T., Sasaki R., Wang L., Sato K., Satoh S., et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000, 60:305-308.
68. Hamasaki T., Inatomi H., Katoh T., Ikuyama T., Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr. J. 2001, 48:543-549.
69. Hamasaki T., Inatomi H., Katoh T., Ikuyama T., Matsumoto T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol. Int. 2002, 68:226-231.
70. Medeiros R., Morais A., Vasconcelos A., Costa S., Pinto D., Oliveira J., et al. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J. Hum. Genet. 2002, 47:413-418.
71. Xu Y., Shibata A., McNeal J.E., Stamey T.A., Feldman D., Peehl D.M. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol. Biomarkers Prev. 2003, 12:23-27.
72. Watanabe M., Fukutome K., Murata M., Uemura H., Kubota Y., Kawamura J., et al. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res. 1999, 19:4511-4514.
73. Blazer D.G., Umbach D.M., Bostick R.M., Taylor J.A. Vitamin D receptor polymorphisms and prostate cancer. Mol. Carcinog. 2000, 27:18-23.
74. Gsur A., Madersbacher S., Haidinger G., Schatzl G., Marberger M., Vutuc C., et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002, 51:30-34.
75. Suzuki K., Matsui H., Ohtake N., Nakata S., Takei T., Koike H., et al. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int. J. Urol. 2003, 10:261-266.
76. Tayeb M.T., Clark C., Haites N.E., Sharp L., Murray G.I., McLeod H.L. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer 2003, 88:928-932.
77. Bodiwala D., Luscombe C.J., French M.E., Liu S., Saxby M.F., Jones P.W., et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ. Mol. Mutagen. 2004, 43:121-127.
78. Curran J.E., Vaughan T., Lea R.A., Weinstein S.R., Morrison N.A., Griffiths L.R. Association of a vitamin D receptor polymorphism with sporadic breast cancer development. Int. J. Cancer 1999, 83:723-726.
79. Lundin A.C., Soderkvist P., Eriksson B., Bergman-Jungestrom M., Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res. 1999, 59:2332-2334.
80. Ingles S.A., Garcia D.G., Wang W., Nieters A., Henderson B.E., Kolonel L.N., et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000, 11:25-30.
81. Bretherton-Watt D., Given-Wilson R., Mansi J.L., Thomas V., Carter N., Colston K.W. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br. J. Cancer 2001, 85:171-175.
82. Hou M.F., Tien Y.C., Lin G.T., Chen C.J., Liu C.S., Lin S.Y., et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res. Treat. 2002, 74:1-7.
83. Schondorf T., Eisberg C., Wassmer G., Warm M., Becker M., Rein D.T., et al. Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology 2003, 64:154-159.
84. Dunning A.M., McBride S., Gregory J., Durocher F., Foster N.A., Healey C.S., et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 1999, 20:2131-2135.
85. Ingles S.A., Wang J., Coetzee G.A., Lee E.R., Frankl H.D., Haile R.W. Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 2001, 12:607-614.
86. Slatter M.L., Yakumo K., Hoffman M., Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 2001, 12:359-364.
87. Peters U., McGlynn K.A., Chatterjee N., Gunter E., Garcia-Closas M., Rothman N., et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1267-1274.
88. Poynter J.N., Jacobs E.T., Figueiredo J.C., Lee W.H., Conti D.V., Campbell P.T., et al. Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 2010, 19:525-536.
89. Ramachandran S., Fryer A.A., Smith A.G., Lear J.T., Bowers B., Hartland A.J., et al. Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics 2001, 11:247-254.
90. Ikuyama T., Hamasaki T., Inatomi H., Katoh T., Muratani T., Matsumoto T. Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. Endocr. J. 2002, 49:433-438.
91. Hutchinson P.E., Osborne J.E., Lear J.T., Smith A.G., Bowers P.W., Morris P.N., et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin. Cancer Res. 2000, 6:498-504.
92. Speer G., Dworak O., Cseh K., Bori Z., Salamon D., Torok I., et al. Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer. Oncology 2000, 58:242-247.
93. Ma J., Stampfer M.J., Gann P.H., Hough H.L., Giovannucci E., Kelsey K.T., et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomarkers Prev. 1998, 7:385-390.
94. Kim H.S., Newcomb P.A., Ulrich C.M., Keener C.L., Bigler J., Farin F.M., et al. Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol. Biomarkers Prev. 2001, 10:869-874.
95. Wong H.L., Seow A., Arakawa K., Lee H.P., Yu M.C., Ingles S.A. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 2003, 24:1091-1095.
96. Durrin L.K., Haile R.W., Ingles S.A., Coetzee G.A. Vitamin D receptor 3'-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim. Biophys. Acta 1999, 1453:311-320.
97. Arai H., Miyamoto K.I., Yoshida M., Yamamoto H., Taketani Y., Morita K., et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 2001, 16:1256-1264.
98. Yamamoto H., Miyamoto K., Li B., Taketani Y., Kitano M., Inoue Y., et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J. Bone Miner. Res. 1999, 14:240-247.
99. d'Alesio A., Garabedian M., Sabatier J.P., Guaydier-Souquieres G., Marcelli C., Lemacon A., et al. Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls. Hum. Mol. Genet. 2005, 14:3539-3548.
100. Jehan F., d'Alesio A., Garabedian M. Exons and functional regions of the human vitamin D receptor gene around and within the main 1a promoter are well conserved among mammals. J. Steroid Biochem. Mol. Biol. 2007, 103:361-367.
101. Colston K., Colston M.J., Feldman D. 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108:1083-1086.
102. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1981, 78:4990-4994.
103. Miyaura C., Abe E., Kuribayashi T., Tanaka H., Konno K., Nishii Y., et al. 1 Alpha,25-dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 1981, 102:937-943.
104. Suda T., Miyaura C., Abe E., Kuroki T. Modulation of cell differentiation, immune responses and tumor promotion by vitamin D compounds 1986, 1-48. Elsevier, Amsterdam. W.A. Peck (Ed.).
105. Suda T., Takahashi N., Abe E. Role of vitamin D in bone resorption. J. Cell Biochem. 1992, 49:53-58.
106. Suda T., Udagawa N., Nakamura I., Miyaura C., Takahashi N. Modulation of osteoclast differentiation by local factors. Bone 1995, 17:87S-91S.
107. Wu J.C., Smith M.W., Lawson D.E. Time dependency of 1,25(OH)2D3 induction of calbindin mRNA and calbindin expression in chick enterocytes during their differentiation along the crypt-villus axis. Differentiation 1992, 51:195-200.
108. Honma Y., Hozumi M., Abe E., Konno K., Fukushima M., Hata S., et al. 1 Alpha,25-dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc. Natl. Acad. Sci. USA 1983, 80:201-204.
109. Sato T., Takusagawa K., Asoo N., Konno K. Antitumor effect of 1 alpha-hydroxyvitamin D3. Tohoku. J. Exp. Med. 1982, 138:445-446.
110. Wood A.W., Chang R.L., Huang M.T., Uskokovic M., Conney A.H. 1 Alpha, 25-dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem. Biophys. Res. Commun. 1983, 116:605-611.
111. Chida K., Hashiba H., Fukushima M., Suda T., Kuroki T. Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1985, 45:5426-5430.
112. Eisman J.A., Barkla D.H., Tutton P.J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987, 47:21-25.
113. Cohen S.M., Saulenas A.M., Sullivan C.R., Albert D.M. Further studies of the effect of vitamin D on retinoblastoma. Inhibition with 1,25-dihydroxycholecalciferol. Arch. Ophthalmol. 1988, 106:541-543.
114. Eisman J.A., Koga M., Sutherland R.L., Barkla D.H., Tutton P.J. 1,25-Dihydroxyvitamin D3 and the regulation of human cancer cell replication. Proc. Soc. Exp. Biol. Med. 1989, 191:221-226.
115. Colston K.W., Berger U., Coombes R.C. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, 1:188-191.
116. Albert D.M., Marcus D.M., Gallo J.P., O'Brien J.M. The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest. Ophthalmol. Vis. Sci. 1992, 33:2354-2364.
117. Belleli A., Shany S., Levy J., Guberman R., Lamprecht S.A. A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis 1992, 13:2293-2298.
118. Iino Y., Yoshida M., Sugamata N., Maemura M., Ohwada S., Yokoe T., et al. 1 Alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Breast Cancer Res. Treat. 1992, 22:133-140.
119. Haq M., Kremer R., Goltzman D., Rabbani S.A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J. Clin Invest. 1993, 91:2416-2422.
120. Tsuchiya H., Morishita H., Tomita K., Ueda Y., Tanaka M. Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma. J. Orthop. Res. 1993, 11:122-130.
121. Young M.R., Halpin J., Hussain R., Lozano Y., Djordjevic A., Devata S., et al. Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invasion Metastasis 1993, 13:169-177.
122. Cohen-Solal M.E., Bouizar Z., Denne M.A., Graulet A.M., Gueris J., Bracq S., et al. 1,25 Dihydroxyvitamin D and dexamethasone decrease in vivo Walker carcinoma growth, but not parathyroid hormone related protein secretion. Horm. Metab. Res. 1995, 27:403-407.
123. Young M.R., Ihm J., Lozano Y., Wright M.A., Prechel M.M. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol. Immunother. 1995, 41:37-45.
124. Young M.R., Lozano Y., Ihm J., Wright M.A., Prechel M.M. Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett. 1996, 104:153-161.
125. Getzenberg R.H., Light B.W., Lapco P.E., Konety B.R., Nangia A.K., Acierno J.S., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997, 50:999-1006.
126. Lokeshwar B.L., Schwartz G.G., Selzer M.G., Burnstein K.L., Zhuang S.H., Block N.L., et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 1999, 8:241-248.
127. Masood R., Nagpal S., Zheng T., Cai J., Tulpule A., Smith D.L., et al. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 2000, 96:3188-3194.
128. Polek T.C., Murthy S., Blutt S.E., Boehm M.F., Zou A., Weigel N.L., et al. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 2001, 49:224-233.
129. Kunakornsawat S., Rosol T.J., Capen C.C., Reddy G.S., Binderup L., Inpanbutr N. Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogues (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice. Biol. Pharm. Bull. 2002, 25:642-647.
130. Oades G.M., Dredge K., Kirby R.S., Colston K.W. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 2002, 90:607-616.
131. Vegesna V., O'Kelly J., Said J., Uskokovic M., Binderup L., Koeffle H.P. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res. 2003, 23:283-289.
132. Zhou J.Y., Norman A.W., Chen D.L., Sun G.W., Uskokovic M., Koeffler H.P. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA 1990, 87:3929-3932.
133. Abe J., Nakano T., Nishii Y., Matsumoto T., Ogata E., Ikeda K. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991, 129:832-837.
134. Colston K., Mackay A.G., Chandler S., Binderup L., Coombes R.C. Novel vitamin D analogues suppress tumour growth in vivo. Gene Regulation, Structure-Function Analysis and Clinical Application 1991, 465-466. De Gruyter, Berlin. A.W. Norman, R. Bouillon, M. Thomasset, D. Vitamin (Eds.).
135. Oikawa T., Yoshida Y., Shimamura M., Ashino-Fuse H., Iwaguchi T., Tominaga T. Antitumor effect of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 1991, 2:475-480.
136. Colston K.W., Chander S.K., Mackay A.G., Coombes R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 1992, 44:693-702.
137. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 1992, 44:2273-2280.
138. Abe-Hashimoto J., Kikuchi T., Matsumoto T., Nishii Y., Ogata E., Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 1993, 53:2534-2537.
139. Anzano M.A., Smith J.M., Uskokovic M.R., Peer C.W., Mullen L.T., Letterio J.J., et al. 1 Alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 1994, 54:1653-1656.
140. Tanaka Y., Wu A.Y., Ikekawa N., Iseki K., Kawai M., Kobayashi Y. Inhibition of HT-29 human colon cancer growth under the renal capsule of severe combined immunodeficient mice by an analogue of 1,25-dihydroxyvitamin D3, DD-003. Cancer Res. 1994, 54:5148-5153.
141. Otoshi T., Iwata H., Kitano M., Nishizawa Y., Morii H., Yano Y., et al. Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1 alpha, 25-dihydroxyvitamin D3. Carcinogenesis 1995, 16:2091-2097.
142. Schwartz G.G., Hill C.C., Oeler T.A., Becich M.J., Bahnson R.R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 1995, 46:365-369.
143. Wali R.K., Bissonnette M., Khare S., Hart J., Sitrin M.D., Brasitus T.A. 1 Alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer Res. 1995, 55:3050-3054.
144. Akhter J., Chen X., Bowrey P., Bolton E.J., Morris D.L. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 1997, 40:317-321.
145. VanWeelden K., Flanagan L., Binderup L., Tenniswood M., Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 1998, 139:2102-2110.
146. Nickerson T., Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J. Endocrinol. 1999, 160:223-229.
147. Blutt S.E., Polek T.C., Stewart L.V., Kattan M.W., Weigel N.L. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000, 60:779-782.
148. Dawson D.G., Gleiser J., Zimbric M.L., Darjatmoko S.R., Lindstrom M.J., Strugnell S.A., et al. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice. Ophthalmology 2003, 110:835-839.
149. Mehta R.G., Hussain E.A., Mehta R.R., Das Gupta T.K. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mutat. Res. 2003, 523-524:253-264.
150. Eelen G., Gysemans C., Verlinden L., Vanoirbeek E., De Clercq P., Van Haver D., et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr. Med. Chem. 2007, 14:1893-1910.
151. Cunningham D., Gilchrist N.L., Cowan R.A., Forrest G.J., McArdle C.S., Soukop M. Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Clin. Res 1985, 291. 1153-1155. J. Br Med (Ed.).
152. Raina V., Cunningham D., Gilchrist N., Soukop M. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br. J. Cancer 1991, 63:463-465.
153. Koeffler H.P., Hirji K., Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep. 1985, 69:1399-1407.
154. Kelsey S.M., Newland A.C., Cunningham J., Makin H.L., Coldwell R.D., Mills M.J., et al. Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes. Lancet 1992, 340:316-317.
155. French L.E., Ramelet A.A., Saurat J.H. Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin. Lancet 1994, 344:686-687.
156. Majewski S., Skopinska M., Bollag W., Jablonska S. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet 1994, 344:1510-1511.
157. Thomsen K. Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment. Lancet 1995, 345:1583.
158. French L.E., Saurat J.H. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol. Lancet 1995, 346:376.
159. Bagot M. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol. Lancet 1995, 346:376-377.
160. Gross C., Stamey T., Hancock S., Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 1998, 159:2035-2039.
161. Beer T.M., Lemmon D., Lowe B.A., Henner W.D. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003, 97:1217-1224.
162. Smith D.C., Johnson C.S., Freeman C.C., Muindi J., Wilson J.W., Trump D.L. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin. Cancer Res. 1999, 5:1339-1345.
163. Beer T.M., Munar M., Henner W.D. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91:2431-2439.
164. Krishnan A.V., Trump D.L., Johnson C.S., Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 2010, 39:401-418. table of contents.
165. Bower M., Colston K.W., Stein R.C., Hedley A., Gazet J.C., Ford H.T., et al. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991, 337:701-702.
166. Gulliford T., English J., Colston K.W., Menday P., Moller S., Coombes R.C. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 1998, 78:6-13.
167. Evans T.R., Colston K.W., Lofts F.J., Cunningham D., Anthoney D.A., Gogas H., et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 2002, 86:680-685.
168. Trump D.L., Muindi J., Fakih M., Yu W.D., Johnson C.S. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res. 2006, 26:2551-2556.
169. Vijayakumar S., Mehta R.R., Boerner P.S., Packianathan S., Mehta R.G. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J. 2005, 11:362-373.
170. Vijayakumar S., Boerner P.S., Mehta R.R., Packianathan S., Mehta R.G., Das Gupta T.K. Clinical trials using chemopreventive vitamin D analogs in breast cancer. Cancer J. 2006, 12:445-450.
171. Majewski S., Szmurlo A., Marczak M., Jablonska S., Bollag W. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett. 1993, 75:35-39.
172. Majewski S., Marczak M., Szmurlo A., Jablonska S., Bollag W. Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett. 1995, 89:117-124.
173. Bernardi R.J., Johnson C.S., Modzelewski R.A., Trump D.L. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143:2508-2514.
174. Shokravi M.T., Marcus D.M., Alroy J., Egan K., Saornil M.A., Albert D.M. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest. Ophthalmol. Vis. Sci. 1995, 36:83-87.
175. Ding I., Sun J.Z., Fenton B., Liu W.M., Kimsely P., Okunieff P., et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 2001, 61:526-531.
176. Marneros A.G., Olsen B.R. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 2001, 20:337-345.
177. Fernandez-Garcia N.I., Palmer H.G., Garcia M., Gonzalez-Martin A., del Rio M., Barettino D., et al. 1Alpha,25-dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 2005, 24:6533-6544.
178. Kanda S., Mochizuki Y., Miyata Y., Kanetake H., Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J. Natl. Cancer Inst. 2002, 94:1311-1319.
179. Kisker O., Onizuka S., Becker C.M., Fannon M., Flynn E., D'Amato R., et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003, 5:32-40.
180. Nowicka D., Zagozdzon R., Majewski S., Marczak M., Jablonska S., Bollag W. Calcitriol enhances antineoplastic and antiangiogenic effects of interleukin-12. Arch. Dermatol. Res. 1998, 290:696-700.
181. Hansen C.M., Frandsen T.L., Brunner N., Binderup L. 1 Alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin. Exp. Metastasis 1994, 12:195-202.
182. Koli K., Keski-Oja J. 1Alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000, 11:221-229.
183. El Abdaimi K., Dion N., Papavasiliou V., Cardinal P.E., Binderup L., Goltzman D., et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000, 60:4412-4418.
184. Bao B.Y., Yeh S.D., Lee Y.F. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006, 27:32-42.
185. Arguello F., Baggs R.B., Frantz C.N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988, 48:6876-6881.
186. Ooi L.L., Zhou H., Kalak R., Zheng Y., Conigrave A.D., Seibel M.J., et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010, 70:1835-1844.
187. Agha F.P., Norman A., Hirschl S., Klein R. Paget's disease. Coexistence with metastatic carcinoma. NY State J. Med. 1976, 76:734-735.
188. Orr W., Varani J., Gondex M.K., Ward P.A., Mundy G.R. Chemotactic responses of tumor cells to products of resorbing bone. Science 1979, 203:176-179.
189. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995, 55:3551-3557.
190. Akech J., Wixted J.J., Bedard K., van der Deen M., Hussain S., Guise T.A., et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821.
191. Paredes R., Arriagada G., Cruzat F., Olate J., Van Wijnen A., Lian J., et al. The Runx2 transcription factor plays a key role in the 1alpha,25-dihydroxy vitamin D3-dependent upregulation of the rat osteocalcin (OC) gene expression in osteoblastic cells. J. Steroid Biochem. Mol. Biol. 2004, 89-90:269-271.
192. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. 1986, 78:1296-1301.
193. Mackey S.L., Heymont J.L., Kronenberg H.M., Demay M.B. Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol. Endocrinol. 1996, 10:298-305.
194. Moseley J.M., Gillespie M.T. Parathyroid hormone-related protein. Crit. Rev. Clin. Lab. Sci. 1995, 32:299-343.
195. Deftos L.J., Barken I., Burton D.W., Hoffman R.M., Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem. Biophys. Res. Commun. 2005, 327:468-472.
196. Akhtari M., Mansuri J., Newman K.A., Guise T.M., Seth P. Biology of breast cancer bone metastasis. Cancer Biol. Ther. 2008, 7:3-9.
197. Sebag M., Henderson J., Goltzman D., Kremer R. Regulation of parathyroid hormone-related peptide production in normal human mammary epithelial cells in vitro. Am. J. Physiol. 1994, 267:C723-C730.
198. Werkmeister J.R., Merryman J.I., McCauley L.K., Horton J.E., Capen C.C., Rosol T.J. Parathyroid hormone-related protein production by normal human keratinocytes in vitro. Exp. Cell Res. 1993, 208:68-74.
199. Kremer R., Karaplis A.C., Henderson J., Gulliver W., Banville D., Hendy G.N., et al. Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. J. Clin. Invest. 1991, 87:884-893.
200. Henderson J., Sebag M., Rhim J., Goltzman D., Kremer R. Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression. Cancer Res. 1991, 51:6521-6528.
201. Yu J., Papavasiliou V., Rhim J., Goltzman D., Kremer R. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 1995, 6:101-108.
202. Falzon M. The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression. Mol. Cell Endocrinol. 1997, 127:99-108.
203. Inoue D., Matsumoto T., Ogata E., Ikeda K. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells. J. Biol. Chem. 1993, 268:16730-16736.
204. Liu B., Goltzman D., Rabbani S.A. Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. Endocrinology 1993, 132:1658-1664.
205. Tovar Sepulveda V.A., Falzon M. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE. Mol. Cell Endocrinol. 2003, 204:51-64.
206. Sepulveda V.A., Weigel N.L., Falzon M. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids 2006, 71:102-115.
207. Tovar S.V., Falzon M. Regulation of PTH-related protein gene expression by vitamin D in PC-3 prostate cancer cells. Mol. Cell Endocrinol. 2002, 190:115-124.
208. Shen X., Falzon M. Parathyroid hormone-related protein upregulates integrin expression via an intracrine pathway in PC-3 prostate cancer cells. Regul. Pept. 2003, 113:17-29.
209. Shen X., Falzon M. PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol. Cell Endocrinol. 2003, 199:165-177.
210. El Abdaimi K., Papavasiliou V., Rabbani S.A., Rhim J.S., Goltzman D., Kremer R. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. Cancer Res. 1999, 59:3325-3328.
211. Endo K., Ichikawa F., Uchiyama Y., Katsumata K., Ohkawa H., Kumaki K., et al. Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J. Biol. Chem. 1994, 269:32693-32699.
212. Merryman J.I., Capen C.C., McCauley L.K., Werkmeister J.R., Suter M.M., Rosol T.J. Regulation of parathyroid hormone-related protein production by a squamous carcinoma cell line in vitro. Lab. Invest. 1993, 69:347-354.
213. Kunakornsawat S., Rosol T.J., Capen C.C., Middleton R.P., Hannah S.S., Inpanbutr N. Effects of 1,25(OH)2D3, EB1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88. Anticancer Res. 2001, 21:3355-3363.
214. Chatterjee M. Vitamin D and genomic stability. Mutat. Res. 2001, 475:69-87.
215. Saha B.K., Bishayee A., Kanjilal N.B., Chatterjee M. 1Alpha,25-dihydroxyvitamin D3 inhibits hepatic chromosomal aberrations, DNA strand breaks and specific DNA adducts during rat hepatocarcinogenesis. Cell Mol. Life Sci. 2001, 58:1141-1149.
216. Akutsu N., Lin R., Bastien Y., Bestawros A., Enepekides D.J., Black M.J., et al. Regulation of gene expression by 1alpha,25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 2001, 15:1127-1139.
217. Fedirko V., Bostick R.M., Long Q., Flanders W.D., McCullough M.L., Sidelnikov E., et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 2010, 19:280-291.
218. Gartel A.L., Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp. Cell Res. 2003, 283:17-21.
219. Karmali R., Bhalla A.K., Farrow S.M., Williams M.M., Lal S., Lydyard P.M., et al. Early regulation of c-myc mRNA by 1,25-dihydroxyvitamin D3 in human myelomonocytic U937 cells. J. Mol. Endocrinol. 1989, 3:43-48.
220. Koizumi T., Nakao Y., Kawanishi M., Maeda S., Sugiyama T., Fujita T. Suppression of c-myc mRNA expression by steroid hormones in HTLV-I-infected T-cell line, KH-2. Int. J. Cancer 1989, 44:701-706.
221. Moore D.C., Carter D.L., Studzinski G.P. Inhibition by 1,25 dihydroxyvitamin D3 of c-myc down-regulation and DNA fragmentation in cytosine arabinoside-induced erythroid differentiation of K562 cells. J. Cell Physiol. 1992, 151:539-548.
222. Sebag M., Henderson J., Rhim J., Kremer R. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. J. Biol. Chem. 1992, 267:12162-12167.
223. Saunders D.E., Christensen C., Wappler N.L., Schultz J.F., Lawrence W.D., Malviya V.K., et al. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993, 4:201-208.
224. Kasukabe T., Okabe-Kado J., Hozumi M., Honma Y. Inhibition by interleukin 4 of leukemia inhibitory factor-, interleukin 6-, and dexamethasone-induced differentiation of mouse myeloid leukemia cells: role of c-myc and junB proto-oncogenes. Cancer Res. 1994, 54:592-597.
225. Taoka T., Collins E.D., Irino S., Norman A.W. 1,25(OH)2-vitamin D3 mediated changes in mRNA for c-myc and 1,25(OH)2D3 receptor in HL-60 cells and related subclones. Mol. Cell Endocrinol. 1993, 95:51-57.
226. Stio M., Celli A., Treves C. Synergistic anti-proliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. J. Steroid Biochem. Mol. Biol. 2001, 77:213-222.
227. Pan Q., Martell R.E., O'Connell T.D., Simpson R.U. 1,25-Dihydroxyvitamin D3-regulated binding of nuclear proteins to a c-myc intron element. Endocrinology 1996, 137:4154-4160.
228. Pan Q., Simpson R.U. C-myc intron element-binding proteins are required for 1,25-dihydroxyvitamin D3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4. J. Biol. Chem. 1999, 274:8437-8444.
229. Palmer H.G., Gonzalez-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 2001, 154:369-387.
230. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., van den Bemd G.J., Dorssers L.C., Birkenhager J.C., et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res. 1994, 54:5711-5717.
231. Hulla W., Kallay E., Krugluger W., Peterlik M., Cross H.S. Growth control of human colon-adenocarcinoma-derived Caco-2 cells by vitamin-D compounds and extracellular calcium in vitro: relation to c-myc-oncogene and vitamin-D-receptor expression. Int. J. Cancer 1995, 62:711-716.
232. Trydal T., Lillehaug J.R., Aksnes L., Aarskog D. Regulation of cell growth, c-myc mRNA, and 1,25-(OH)2 vitamin D3 receptor in C3H/10T1/2 mouse embryo fibroblasts by calcipotriol and 1,25-(OH)2 vitamin D3. Acta. Endocrinol. (Copenh) 1992, 126:75-79.
233. Paatero G.I., Trydal T., Karlstedt K.A., Aarskog D., Lillehaug J.R. Time-course study of 1,25-(OH)2-vitamin D3 induction of homologous receptor and c-myc in nontransformed and transformed C3H/10T1/2 cell clones. Int. J. Biochem. 1994, 26:367-374.
234. Mahonen A., Pirskanen A., Maenpaa P.H. Homologous and heterologous regulation of 1,25-dihydroxyvitamin D-3 receptor mRNA levels in human osteosarcoma cells. Biochim. Biophys. Acta. 1991, 1088:111-118.
235. van den Bemd G.J., Pols H.A., Birkenhager J.C., Kleinekoort W.M., van Leeuwen J.P. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption. J. Steroid Biochem. Mol. Biol. 1995, 55:337-346.
236. Casado M., Bosch J., Garcia-Pagan J.C., Bru C., Banares R., Bandi J.C., et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998, 114:1296-1303.
237. Rohan J.N., Weigel N.L. 1Alpha,25-dihydroxyvitamin D3 reduces c-myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009, 150:2046-2054.
238. Brelvi Z.S., Christakos S., Studzinski G.P. Expression of monocyte-specific oncogenes c-fos and c-fms in HL60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Lab. Invest. 1986, 55:269-275.
239. Huh N., Satoh M., Nose K., Abe E., Suda T., Rajewsky M.F., et al. 1 Alpha,25-dihydroxyvitamin D3 induces anchorage-independent growth and c-Ki-ras expression of BALB/3T3 and NIH/3T3 cells. Jpn. J. Cancer Res. 1987, 78:99-102.
240. Lasky S.R., Iwata K., Rosmarin A.G., Caprio D.G. Maizel AL 1995 Differential regulation of JunD by dihydroxycholecalciferol in human chronic myelogenous leukemia cells. J. Biol. Chem. 1967, 270:19676-19679.
241. Khare S., Bolt M.J., Wali R.K., Skarosi S.F., Roy H.K., Niedziela S., et al. 1,25 Dihydroxyvitamin D3 stimulates phospholipase C-gamma in rat colonocytes: role of c-Src in PLC-gamma activation. J. Clin. Invest. 1997, 99:1831-1841.
242. Khare S., Bissonnette M., Wali R., Skarosi S., Boss G.R., von Lintig F.C., et al. 1,25-Dihydroxyvitamin D3 but not TPA activates PLD in Caco-2 cells via pp60(c-src) and RhoA. Am. J. Physiol. 1999, 276:G1005-G1015.
243. Johansen C., Kragballe K., Henningsen J., Westergaard M., Kristiansen K., Iversen L. 1Alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expression in human keratinocytes. J. Invest. Dermatol. 2003, 120:561-570.
244. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 2008, 8:714-724.
245. Lasky S.R., Posner M.R., Iwata K., Santos-Moore A., Yen A., Samuel V., et al. Characterization of a vitamin D3-resistant human chronic myelogenous leukemia cell line. Blood 1994, 84:4283-4294.
246. Fan F.S., Yu W.C. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest. 1995, 13:280-286.
247. Yen A., Chandler S., Forbes M.E., Fung Y.K., T'Ang A., Pearson R. Coupled down-regulation of the RB retinoblastoma and c-myc genes antecedes cell differentiation: possible role of RB as a "status quo" gene. Eur. J. Cell Biol. 1992, 57:210-221.
248. Yen A., Varvayanis S. Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp. Cell Res. 1994, 214:250-257.
249. Kobayashi T., Hashimoto K., Yoshikawa K. Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem. Biophys. Res. Commun. 1993, 196:487-493.
250. Ehinger M., Bergh G., Olofsson T., Baldetorp B., Olsson I., Gullberg U. Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells. Blood 1996, 87:1064-1074.
251. Davoust N., Wion D., Chevalier G., Garabedian M., Brachet P., Couez D. Vitamin D receptor stable transfection restores the susceptibility to 1,25-dihydroxyvitamin D3 cytotoxicity in a rat glioma resistant clone. J. Neurosci. Res. 1998, 52:210-219.
252. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I.P., et al. 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 1995, 55:2822-2830.
253. Pepper C., Thomas A., Hoy T., Milligan D., Bentley P., Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003, 101:2454-2460.
254. Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Sigfried Z., et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010, 17:273-285.
255. Lee T.H., Pelletier J. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter. Physiol. Genomics 2001, 7:187-200.
256. Adams L.S., Teegarden D. 1,25-Dihydroxycholecalciferol inhibits apoptosis in C3H10T1/2 murine fibroblast cells through activation of nuclear factor kappaB. J. Nutr. 2004, 134:2948-2952.
257. Tse A.K., Wan C.K., Shen X.L., Zhu G.Y., Cheung H.Y., Yang M., et al. 1,25-Dihydroxyvitamin D3 induces biphasic NF-kappaB responses during HL-60 leukemia cells differentiation through protein induction and PI3K/Akt-dependent phosphorylation/degradation of IkappaB. Exp. Cell Res. 2007, 313:1722-1734.
258. Berry D.M., Clark C.S., Meckling-Gill K.A. 1Alpha,25-dihydroxyvitamin D3 stimulates phosphorylation of IkappaBalpha and synergizes with TPA to induce nuclear translocation of NFkappaB during monocytic differentiation of NB4 leukemia cells. Exp. Cell Res. 2002, 272:176-184.
259. Riis J.L., Johansen C., Gesser B., Moller K., Larsen C.G., Kragballe K., et al. 1Alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch. Dermatol. Res. 2004, 296:195-202.
260. Cohen-Lahav M., Shany S., Tobvin D., Chaimovitz C., Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol. Dial. Transplant. 2006, 21:889-897.
261. Sun J., Mustafi R., Cerda S., Chumsangsri A., Xia Y.R., Li Y.C., et al. Lithocholic acid down-regulation of NF-kappaB activity through vitamin D receptor in colonic cancer cells. J. Steroid Biochem. Mol. Biol. 2008, 111:37-40.
262. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E315-322.
263. Tse A.K., Zhu G.Y., Wan C.K., Shen X.L., Yu Z.L., Fong W.F. 1Alpha,25-dihydroxyvitamin D(3) inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol. Immunol. 2010.
264. Kovalenko P.L., Zhang Z., Cui M., Clinton S.K., Fleet J.C. 1,25 Dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 2010, 11:26.
265. Krishnan A.V., Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer 2010, 17:R19-38.
266. Chen K.S., DeLuca H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim. Biophys. Acta. 1994, 1219:26-32.
267. Nishiyama A., Matsui M., Iwata S., Hirota K., Masutani H., Nakamura H., et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem. 1999, 274:21645-21650.
268. Nishiyama A., Masutani H., Nakamura H., Nishinaka Y., Yodoi J. Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life 2001, 52:29-33.
269. Ikarashi M., Takahashi Y., Ishii Y., Nagata T., Asai S., Ishikawa K. Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res. 2002, 22:4045-4048.
270. Takahashi Y., Nagata T., Ishii Y., Ikarashi M., Ishikawa K., Asai S. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol. Rep. 2002, 9:75-79.
271. Schulze P.C., De Keulenaer G.W., Yoshioka J., Kassik K.A., Lee R.T. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ. Res. 2002, 91:689-695.
272. Wang Y., De Keulenaer G.W., Lee R.T. Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J. Biol. Chem. 2002, 277:26496-26500.
273. Han S.H., Jeon J.H., Ju H.R., Jung U., Kim K.Y., Yoo H.S., et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydroxyvitamin D(3) inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 2003, 22:4035-4046.
274. Song H., Cho D., Jeon J.H., Han S.H., Hur D.Y., Kim Y.S., et al. Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species. Immunol. Lett. 2003, 86:235-247.
275. Ward J.O., McConnell M.J., Carlile G.W., Pandolfi P.P., Licht J.D., Freedman L.P. The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. Blood 2001, 98:3290-3300.
276. Puccetti E., Obradovic D., Beissert T., Bianchini A., Washburn B., Chiaradonna F., et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res. 2002, 62:7050-7058.
277. Yamamoto Y., Sakamoto M., Fujii G., Kanetaka K., Asaka M., Hirohashi S. Cloning and characterization of a novel gene, DRH1, down-regulated in advanced human hepatocellular carcinoma. Clin. Cancer Res. 2001, 7:297-303.
278. Jakob F., Homann D., Adamski J. Expression and regulation of aromatase and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells. J. Steroid Biochem. Mol. Biol. 1995, 55:555-563.
279. Hughes S.V., Robinson E., Bland R., Lewis H.M., Stewart P.M., Hewison M. 1,25-Dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes. Endocrinology 1997, 138:3711-3718.
280. Hughes P.J., Twist L.E., Durham J., Choudhry M.A., Drayson M., Chandraratna R., et al. Up-regulation of steroid sulphatase activity in HL60 promyelocytic cells by retinoids and 1alpha,25-dihydroxyvitamin D3. Biochem. J. 2001, 355:361-371.
281. Enjuanes A., Garcia-Giralt N., Supervia A., Nogues X., Mellibovsky L., Carbonell J., et al. Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur. J. Endocrinol. 2003, 148:519-526.
282. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 151:32-42.
283. Reichman T.W., Albanell J., Wang X., Moore M.A., Studzinski G.P. Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. J. Cell Biochem. 1997, 67:13-23.
284. Rots N.Y., Liu M., Anderson E.C., Freedman L.P. A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol. Cell Biol. 1998, 18:1911-1918.
285. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65:7917-7925.
286. Iyer V.R., Eisen M.B., Ross D.T., Schuler G., Moore T., Lee J.C., et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999, 283:83-87.
287. Whitfield M.L., Sherlock G., Saldanha A.J., Murray J.I., Ball C.A., Alexander K.E., et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 2002, 13:1977-2000.
288. Lin R., Nagai Y., Sladek R., Bastien Y., Ho J., Petrecca K., et al. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 2002, 16:1243-1256.
289. Krishnan A.V., Peehl D.M., Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell Biochem. 2003, 88:363-371.
290. Palmer H.G., Sanchez-Carbayo M., Ordonez-Moran P., Larriba M.J., Cordon-Cardo C., Munoz A. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 2003, 63:7799-7806.
291. Walker P.R., Kwast-Welfeld J., Gourdeau H., Leblanc J., Neugebauer W., Sikorska M. Relationship between apoptosis and the cell cycle in lymphocytes: roles of protein kinase C, tyrosine phosphorylation, and AP1. Exp. Cell Res. 1993, 207:142-151.
292. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28:251-265.
293. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26:239-257.
294. Evans S.R., Soldatenkov V., Shchepotin E.B., Bogrash E., Shchepotin I.B. Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int. J. Oncol. 1999, 14:979-985.
295. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
296. Korsmeyer S.J., McDonnell T.J., Nunez G., Hockenbery D., Young R. Bcl-2: B cell life, death and neoplasia. Curr. Top Microbiol. Immunol. 1990, 166:203-207.
297. Xu H.M., Tepper C.G., Jones J.B., Fernandez C.E., Studzinski G.P. 1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Exp. Cell Res. 1993, 209:367-374.
298. James S.Y., Mackay A.G., Colston K.W. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J. Mol. Endocrinol. 1995, 14:391-394.
299. Danielsson C., Torma H., Vahlquist A., Carlberg C. Positive and negative interaction of 1,25-dihydroxyvitamin D3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. Int. J. Cancer 1999, 81:467-470.
300. Mathiasen I.S., Lademann U., Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999, 59:4848-4856.
301. Narvaez C.J., Zinser G., Welsh J. Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 2001, 66:301-308.
302. Mathiasen I.S., Sergeev I.N., Bastholm L., Elling F., Norman A.W., Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J. Biol. Chem. 2002, 277:30738-30745.
303. Malloy P.J., Feldman D. Inactivation of the human vitamin D receptor by caspase-3. Endocrinology 2009, 150:679-686.
304. Guzey M., Kitada S., Reed J.C. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol. Cancer Ther. 2002, 1:667-677.
305. Baudet C., Perret E., Delpech B., Kaghad M., Brachet P., Wion D., et al. Differentially expressed genes in C6.9 glioma cells during vitamin D-induced cell death program. Cell Death Differ. 1998, 5:116-125.
306. Holt P.R., Bresalier R.S., Ma C.K., Liu K.F., Lipkin M., Byrd J.C., et al. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa. Cancer 2006, 106:287-296.
307. Fedirko V., Bostick R.M., Flanders W.D., Long Q., Shaukat A., Rutherford R.E., et al. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev. Res. (Phila Pa) 2009, 2:213-223.
308. Wallington L.A., Bunce C.M., Durham J., Brown G. Particular combinations of signals, by retinoic acid and 1 alpha, 25 dihydroxyvitamin D3, promote apoptosis of HL60 cells. Leukemia 1995, 9:1185-1190.
309. Wu Y.L., Jiang X.R., Lillington D.M., Allen P.D., Newland A.C., Kelsey S.M. 1,25-Dihydroxyvitamin D3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2. Cancer Res. 1998, 58:633-640.
310. Witcher M., Yang X., Pater A., Tang S.C. BAG-1 p50 isoform interacts with the vitamin D receptor and its cellular overexpression inhibits the vitamin D pathway. Exp. Cell Res. 2001, 265:167-173.
311. Christakos S., Barletta F., Huening M., Dhawan P., Liu Y., Porta A., et al. Vitamin D target proteins: function and regulation. J. Cell Biochem. 2003, 88:238-244.
312. Hoyer-Hansen M., Bastholm L., Mathiasen I.S., Elling F., Jaattela M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 2005, 12:1297-1309.
313. Demasters G., Di X., Newsham I., Shiu R., Gewirtz D.A. Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery. Mol. Cancer Ther. 2006, 5:2786-2797.
314. Gocek E., Studzinski G.P. Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci. 2009, 46:190-209.
315. Gocek E., Kielbinski M., Baurska H., Haus O., Kutner A., Marcinkowska E. Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations. Leuk Res. 2010, 34:649-657.
316. Bikle D.D., Pillai S. Vitamin D, calcium, and epidermal differentiation. Endocr. Rev. 1993, 14:3-19.
317. Hosoi J., Abe E., Suda T., Kuroki T. Regulation of melanin synthesis of
318. van Leeuwen J.P., van Steenbrugge G.J., Veldscholte J., van den Bemd G.J., Oomen M.H.A., Pols H.A., et al. Growth regulation of three sublines of the human prostatic carcinoma line LNCaP by an interrelated action of 1,25-dihydroxyvitamin D3 and androgens. Vitamin D, Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical applIcation 1994, 510-511. de Gruyter, Berlin. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
319. Esquenet M., Swinnen J.V., Heyns W., Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996, 28:182-194.
320. Zhao X.Y., Ly L.H., Peehl D.M., Feldman D. 1Alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997, 138:3290-3298.
321. Hedlund T.E., Moffatt K.A., Uskokovic M.R., Miller G.J. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin. Cancer Res. 1997, 3:1331-1338.
322. Frappart L., Falette N., Lefebvre M.F., Bremond A., Vauzelle J.L., Saez S. In vitro study of effects of 1,25 dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT.20. Differentiation 1989, 40:63-69.
323. Nagasaki T., Hino M., Inaba M., Nishizawa Y., Morii H., Otani S. Inhibition by 1alpha,25-dihydroxyvitamin D3 of activin A-induced differentiation of murine erythroleukemic F5-5 cells. Arch. Biochem. Biophys. 1997, 343:181-187.
324. Kumagai T., O'Kelly J., Said J.W., Koeffler H.P. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J. Natl. Cancer Inst. 2003, 95:896-905.
325. Ordonez-Moran P., Larriba M.J., Palmer H.G., Valero R.A., Barbachano A., Dunach M., et al. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol. 2008, 183:697-710.
326. Pendas-Franco N., Aguilera O., Pereira F., Gonzalez-Sancho J.M., Munoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res. 2008, 28:2613-2623.
327. Gonzalez-Sancho J.M., Alvarez-Dolado M., Munoz A. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 1998, 426:225-228.
328. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75:193-207.
329. Lefebvre M.F., Guillot C., Crepin M., Saez S. Influence of tumor derived fibroblasts and 1,25-dihydroxyvitamin D3 on growth of breast cancer cell lines. Breast. Cancer Res. Treat. 1995, 33:189-197.
330. Rotello R.J., Lieberman R.C., Purchio A.F., Gerschenson L.E. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells. Proc. Natl. Acad. Sci. USA 1991, 88:3412-3415.
331. Alexandrow M.G., Moses H.L. Transforming growth factor beta 1 inhibits mouse keratinocytes late in G1 independent of effects on gene transcription. Cancer Res. 1995, 55:3928-3932.
332. Laiho M., Decaprio J.A., Ludlow J.W., Livingston D.M., Massague J. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990, 62:175-185.
333. Simboli-Campbell M., Welsh J. 1,25-Dihydroxyvitamin D3: coordinate regulator of active cell death and proliferation in MCF-7 breast cancer cells. Apoptosis in Hormone Dependent Cancers 1995, 181-200. Springer-Verlag, Berlin. M. Tenniswood, H. Michna (Eds.).
334. Kim H.J., Abdelkader N., Katz M., McLane J.A. 1,25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-beta1 on human keratinocytes in culture. J. Cell Physiol. 1992, 151:579-587.
335. Koli K., Keski-Oja J. Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and -beta 2 in cultured murine keratinocytes. Growth Factors 1993, 8:153-163.
336. Finkelman R.D., Linkhart T.A., Mohan S., Lau K.H., Baylink D.J., Bell N.H. Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor beta in rat bone: possible mechanism for impaired osteoinduction. Proc. Natl. Acad. Sci. USA 1991, 88:3657-3660.
337. Yanagisawa J., Yanagi Y., Masuhiro Y., Suzawa M., Watanabe M., Kashiwagi K., et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999, 283:1317-1321.
338. Yang L., Yang J., Venkateswarlu S., Ko T., Brattain M.G. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J. Cell Physiol. 2001, 188:383-393.
339. Jogie-Brahim S., Feldman D., Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr. Rev. 2009, 30:417-437.
340. Cohen P. Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology 2006, 147:2109-2111.
341. Ingermann A.R., Yang Y.F., Paisley T.E., Han J., Mikami A., Garza A.E., et al. Identification of a novel cell death receptor mediating IGFBP-3-induced antitumor effects in breast and prostate cancer. J. Biol. Chem. 2010.
342. Krishnan A.V., Moreno J., Nonn L., Malloy P., Swami S., Peng L., et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid Biochem. Mol. Biol. 2007, 103:694-702.
343. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., Birkenhager J.C., van Leeuwen J.P. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur. J. Cancer 1996, 32A:842-848.
344. Drivdahl R.H., Loop S.M., Andress D.L., Ostenson R.C. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995, 26:72-79.
345. Velez-Yanguas M.C., Kalebic T., Maggi M., Kappel C.C., Letterio J., Uskokovic M., et al. 1 Alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J. Clin Endocrinol. Metab. 1996, 81:93-99.
346. Moriwake T., Tanaka H., Kanzaki S., Higuchi J., Seino Y. 1,25-Dihydroxyvitamin D3 stimulates the secretion of insulin-like growth factor binding protein 3 (IGFBP-3) by cultured human osteosarcoma cells. Endocrinology 1992, 130:1071-1073.
347. Nakao Y., Hilliker S., Baylink D.J., Mohan S. Studies on the regulation of insulin-like growth factor binding protein 3 secretion in human osteosarcoma cells in vitro. J. Bone Miner. Res. 1994, 9:865-872.
348. Oh Y.S., Kim E.J., Schaffer B.S., Kang Y.H., Binderup L., MacDonald R.G., et al. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol. Cell Endocrinol. 2001, 183:141-149.
349. Chen A., Davis B.H., Sitrin M.D., Brasitus T.A., Bissonnette M. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283:G864-874.
350. Koga M., Eisman J.A., Sutherland R.L. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells. Cancer Res. 1988, 48:2734-2739.
351. Falette N., Frappart L., Lefebvre M.F., Saez S. Increased epidermal growth factor receptor level in breast cancer cells treated by 1,25-dihydroxyvitamin D3. Mol. Cell Endocrinol. 1989, 63:189-198.
352. Tong W.M., Kallay E., Hofer H., Hulla W., Manhardt T., Peterlik M., et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur. J. Cancer 1998, 34:2119-2125.
353. Tong W.M., Hofer H., Ellinger A., Peterlik M., Cross H.S. Mechanism of antimitogenic action of vitamin D in human colon carcinoma cells: relevance for suppression of epidermal growth factor-stimulated cell growth. Oncol. Res. 1999, 11:77-84.
354. Cordero J.B., Cozzolino M., Lu Y., Vidal M., Slatopolsky E., Stahl P.D., et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J. Biol. Chem. 2002, 277:38965-38971.
355. Beildeck M.E., Islam M., Shah S., Welsh J., Byers S.W. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS. One 2009, 4:e7872.
356. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., Birkenhager J.C., van Leeuwen J.P. Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells. Breast Cancer Res. Treat. 1994, 29:161-168.
357. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell Biol. 1994, 72:537-545.
358. Krishnan A.V., Swami S., Feldman D. Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J. Steroid. Biochem. Mol. Biol. 2010.
359. Byrne I.M., Flanagan L., Tenniswood M.P., Welsh J. Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 2000, 141:2829-2836.
360. Wietzke J.A., Welsh J. Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2003, 84:149-157.
361. Fujita N., Jaye D.L., Kajita M., Geigerman C., Moreno C.S., Wade P.A. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113:207-219.
362. Fujita N., Kajita M., Taysavang P., Wade P.A. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol. Endocrinol. 2004, 18:2937-2949.
363. Smirnoff P., Liel Y., Gnainsky J., Shany S., Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol. Res. 1999, 11:255-264.
364. Ahonen M.H., Zhuang Y.H., Aine R., Ylikomi T., Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int. J. Cancer 2000, 86:40-46.
365. Zhao X.Y., Ly L.H., Peehl D.M., Feldman D. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999, 140:1205-1212.
366. Miyaura C., Abe E., Honma Y., Hozumi M., Nishii Y., Suda T. Cooperative effect of 1 alpha,25-dihydroxyvitamin D3 and dexamethasone in inducing differentiation of mouse myeloid leukemia cells. Arch. Biochem. Biophys. 1983, 227:379-385.
367. Yu W.D., McElwain M.C., Modzelewski R.A., Russell D.M., Smith D.C., Trump D.L., et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J. Natl. Cancer Inst. 1998, 90:134-141.
368. Bernardi R.J., Trump D.L., Yu W.D., McGuire T.F., Hershberger P.A., Johnson C.S. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res. 2001, 7:4164-4173.
369. Ziegler R., Kasperk C. Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids 1998, 63:344-348.
370. Koga M., Sutherland R.L. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J. Steroid. Biochem. Mol. Biol. 1991, 39:455-460.
371. Moore T.B., Sidell N., Chow V.J., Medzoyan R.H., Huang J.I., Yamashiro J.M., et al. Differentiating effects of 1,25-dihydroxycholecalciferol (D3) on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid. J. Pediatr. Hematol. Oncol. 1995, 17:311-317.
372. Bunce C.M., Wallington L.A., Harrison P., Williams G.R., Brown G. Treatment of HL60 cells with various combinations of retinoids and 1 alpha,25 dihydroxyvitamin D3 results in differentiation towards neutrophils or monocytes or a failure to differentiate and apoptosis. Leukemia 1995, 9:410-418.
373. Bollag W., Majewski S., Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia 1994, 8:1453-1457.
374. Kliewer S.A., Umesono K., Mangelsdorf D.J., Evans R.M. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992, 355:446-449.
375. Matsui T., Takahashi R., Mihara K., Nakagawa T., Koizumi T., Nakao Y., et al. Cooperative regulation of c-myc expression in differentiation of human promyelocytic leukemia induced by recombinant gamma-interferon and 1,25-dihydroxyvitamin D3. Cancer Res. 1985, 45:4366-4371.
376. Morel P.A., Manolagas S.C., Provvedini D.M., Wegmann D.R., Chiller J.M. Interferon-gamma-induced IA expression in WEHI-3 cells is enhanced by the presence of 1,25-dihydroxyvitamin D3. J. Immunol. 1986, 136:2181-2186.
377. Kelsey S.M., Makin H.L., MacEy M.G., Newland A.C. Gamma interferon augments functional and phenotypic characteristics of vitamin D3-induced monocytoid differentiation in the U937 human leukaemic cell line. Leuk Res. 1990, 14:1027-1033.
378. Kelsey S.M., Coldwell R.D., Makin H.L., Syndercombe C., Newland A.C. Neopterin release by myeloid leukaemic cells can be synergistically augmented by 1,25-dihydroxyvitamin D3 in combination with gamma interferon or granulocyte-macrophage colony stimulating factor. J. Steroid Biochem. Mol. Biol. 1994, 48:95-99.
379. Kasukabe T., Okabe-Kado J., Honma Y., Hozumi M. Interleukin-4 inhibits the differentiation of mouse myeloid leukemia M1 cells induced by dexamethasone, D-factor/leukemia inhibitory factor and interleukin-6, but not by 1 alpha,25-dihydroxyvitamin D3. FEBS Lett. 1991, 291:181-184.
380. Kasukabe T., Okabe-Kado J., Honma Y., Hozumi M. Interleukin 4 potentiates the antiproliferative effect of 1 alpha, 25-dihydroxyvitamin D3 on mouse monocytic leukemia cells but antagonizes the antiproliferative effects of interferon alpha, beta and interleukin 6. Leuk. Res. 1992, 16:1191-1196.
381. Hassan H.T., Tsiriyotis C., Maurer H.R., Spandidos D.A. Recombinant human interleukin-3 opposes the effects of vitamins A and D on HL-60 human myeloid leukaemia cells. Anticancer Res. 1992, 12:821-825.
382. Prechel M.M., Lozano Y., Wright M.A., Ihm J., Young M.R. Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D3 treatments to block induction of immunosuppressive granulocyte/macrophage progenitor cells. Cancer Immunol. Immunother. 1996, 42:213-220.
383. Koren R., Rocker D., Kotestiano O., Liberman U.A., Ravid A. Synergistic anticancer activity of 1,25-dihydroxyvitamin D(3) and immune cytokines: the involvement of reactive oxygen species. J. Steroid Biochem. Mol. Biol. 2000, 73:105-112.
384. Katakami Y., Nakao Y., Katakami N., Koizumi T., Ogawa R., Yamada H., et al. Cooperative effects of tumor necrosis factor-alpha and 1,25-dihydroxyvitamin D3 on growth inhibition, differentiation, and c-myc reduction in human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun. 1988, 152:1151-1157.
385. Rocker D., Ravid A., Liberman U.A., Garach-Jehoshua O., Koren R. 1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol. Cell Endocrinol. 1994, 106:157-162.
386. Hassan H.T., Eliopoulos A., Maurer H.R., Spandidos D.A. Recombinant human GM-CSF enhances the anti-proliferative activity of vitamin D in MCF-7 human breast cancer clonogenic cells. Eur. J. Cancer 1992, 28A:1588-1589.
387. Kelsey S.M., Makin H.L., Newland A.C. Functional significance of induction of differentiation in human myeloid leukaemic blasts by 1,25-dihydroxyvitamin D3 and GM-CSF. Leuk. Res. 1992, 16:427-434.
388. Rashid S.F., Moore J.S., Walker E., Driver P.M., Engel J., Edwards C.E., et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001, 20:1860-1872.
389. Gaschott T., Werz O., Steinmeyer A., Steinhilber D., Stein J. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem. Biophys. Res. Commun. 2001, 288:690-696.
390. Gaschott T., Wachtershauser A., Steinhilber D., Stein J. 1,25-Dihydroxycholecalciferol enhances butyrate-induced p21(Waf1/Cip1) expression. Biochem. Biophys. Res. Commun. 2001, 283:80-85.
391. Bizzarri M., Cucina A., Valente M.G., Tagliaferri F., Borrelli V., Stipa F., et al. Melatonin and vitamin D(3) increase TGF-beta(1) release and induce growth inhibition in breast cancer cell cultures. J. Surg. Res. 2003, 110:332-337.
392. Cho Y.L., Christensen C., Saunders D.E., Lawrence W.D., Deppe G., Malviya V.K., et al. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 1991, 51:2848-2853.
393. Ravid A., Rocker D., Machlenkin A., Rotem C., Hochman A., Kessler-Icekson G., et al. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999, 59:862-867.
394. Sundaram S., Chaudhry M., Reardon D., Gupta M., Gewirtz D.A. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res. Treat. 2000, 63:1-10.
395. Chaudhry M., Sundaram S., Gennings C., Carter H., Gewirtz D.A. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother. Pharmacol. 2001, 47:429-436.
396. Danilenko M., Wang X., Studzinski G.P. Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. J. Natl. Cancer Inst. 2001, 93:1224-1233.
397. Danilenko M., Wang Q., Wang X., Levy J., Sharoni Y., Studzinski G.P. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res. 2003, 63:1325-1332.
398. Gewirtz D.A., Gupta M.S., Sundaram S. Vitamin D3 and vitamin D3 analogues as an adjunct to cancer chemo-therapy and radiotherapy. Curr. Med. Chem. Anti-Canc. Agents 2002, 2:683-690.
399. Polar M.K., Gennings C., Park M., Gupta M.S., Gewirtz D.A. Effect of the vitamin D(3) analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother. Pharmacol. 2003, 51:415-421.
400. Sundaram S., Sea A., Feldman S., Strawbridge R., Hoopes P.J., Demidenko E., et al. The combination of a potent vitamin D(3) analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res. 2003, 9:2350-2356.
401. Beer T.M., Venner P.M., Ryan C.W., Petrylak D.P., Chatta G., Dean Ruether J., et al. High dose calcitriol may reduce thrombosis in cancer patients. Br. J. Haematol. 2006, 135:392-394.
402. Dokoh S., Donaldson C.A., Haussler M.R. Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor. Cancer Res. 1984, 44:2103-2109.
403. Miller G.J., Stapleton G.E., Hedlund T.E., Moffat K.A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1995, 1:997-1003.
404. Hedlund T.E., Moffatt K.A., Miller G.J. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996, 137:1554-1561.
405. Jensen S.S., Madsen M.W., Lukas J., Bartek J., Binderup L. Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with vitamin D receptor protein induction. J. Steroid Biochem. Mol. Biol. 2002, 81:123-133.
406. Tokumoto M., Tsuruya K., Fukuda K., Kanai H., Kuroki S., Hirakata H., et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27. Nephrol. Dial. Transplant. 2003, 18(Suppl 3):III9-III12.
407. Zinser G.M., McEleney K., Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D(3) receptor knockout mice. Mol. Cell Endocrinol. 2003, 200:67-80.
408. Xu H.M., Kolla S.S., Goldenberg N.A., Studzinski G.P. Resistance to 1,25-dihydroxyvitamin D3 of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. Exp. Cell Res. 1992, 203:244-250.
409. Narvaez C.J., VanWeelden K., Byrne I., Welsh J. Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 1996, 137:400-409.
410. Iwata K., Kouttab N., Ogata H., Morgan J.W., Maizel A.L., Lasky S.R. Differential regulation of vitamin D receptors in clonal populations of a chronic myelogenous leukemia cell line. Exp. Cell Res. 1996, 225:143-150.
411. Palmer H.G., Larriba M.J., Garcia J.M., Ordonez-Moran P., Pena C., Peiro S., et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat. Med. 2004, 10:917-919.
412. Larriba M.J., Bonilla F., Munoz A. The transcription factors Snail1 and Snail2 repress vitamin D receptor during colon cancer progression. J. Steroid Biochem. Mol. Biol. 2010.
413. Larriba M.J., Martin-Villar E., Garcia J.M., Pereira F., Pena C., de Herreros A.G., et al. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Carcinogenesis 2009, 30:1459-1468.
414. Mittal M.K., Myers J.N., Misra S., Bailey C.K., Chaudhuri G. In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells. Biochem. Biophys Res. Commun. 2008, 372:30-34.
415. Rozenchan P.B., Folgueira M.A., Katayama M.L., Snitcovsky I.M., Brentani M.M. Ras activation is associated with vitamin D receptor mRNA instability in HC11 mammary cells. J. Steroid Biochem. Mol. Biol. 2004, 92:89-95.
416. Agudo-Ibanez L., Nunez F., Calvo F., Berenjeno I.M., Bustelo X.R., Crespo P. Transcriptomal profiling of site-specific Ras signals. Cell Signal 2007, 19:2264-2276.
417. Khanim F.L., Gommersall L.M., Wood V.H., Smith K.L., Montalvo L., O'Neill L.P., et al. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 2004, 23:6712-6725.
418. Banwell C.M., MacCartney D.P., Guy M., Miles A.E., Uskokovic M.R., Mansi J., et al. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin. Cancer Res. 2006, 12:2004-2013.
419. Narvaez C.J., Byrne B.M., Romu S., Valrance M., Welsh J. Induction of apoptosis by 1,25-dihydroxyvitamin D(3) in MCF-7 vitamin D(3)-resistant variant can be sensitized by TPA. J. Steroid Biochem. Mol. Biol. 2003, 84:199-209.
420. Hansen C.M., Rohde L., Madsen M.W., Hansen D., Colston K.W., Pirianov G., et al. MCF-7/VD(R): a new vitamin D resistant cell line. J. Cell Biochem. 2001, 82:422-436.
421. Wajchmann H.J., Rathod B., Song S., Xu H., Wang X., Uskokovic M.R., et al. Loss of deoxcytidine kinase expression and tetraploidization of HL60 cells following long-term culture in 1,25-dihydroxyvitamin D3. Exp. Cell Res. 1996, 224:312-322.
422. Solomon C., Sebag M., White J.H., Rhim J., Kremer R. Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes. J. Biol. Chem. 1998, 273:17573-17578.
423. Prufer K., Schroder C., Hegyi K., Barsony J. Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol. Mol. Endocrinol. 2002, 16:961-976.
424. Abedin S.A., Banwell C.M., Colston K.W., Carlberg C., Campbell M.J. Epigenetic corruption of VDR signalling in malignancy. Anticancer Res. 2006, 26:2557-2566.
425. Marik R., Fackler M., Gabrielson E., Zeiger M.A., Sukumar S., Stearns V., et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol. Ther. 2010, 10.
426. Yenamandra S.P., Hellman U., Kempkes B., Darekar S.D., Petermann S., Sculley T., et al. Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cell Mol. Life Sci. 2010.
427. Zhuang S.H., Burnstein K.L. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207.
428. Chen H., Hu B., Allegretto E.A., Adams J.S. The vitamin D response element-binding protein. A novel dominant-negative regulator of vitamin D-directed transactivation. J. Biol. Chem. 2000, 275:35557-35564.
429. Chen H., Hewison M., Hu B., Adams J.S. Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: a cause of vitamin D resistance. Proc. Natl. Acad. Sci. USA 2003, 100:6109-6114.
430. Chen T.L., Hauschka P.V., Feldman D. Dexamethasone increases 1,25-dihydroxyvitamin D3 receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 1986, 118:1119-1126.
431. Ly L.H., Zhao X.Y., Holloway L., Feldman D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999, 140:2071-2076.
432. Peehl D.M., Seto E., Hsu J.Y., Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J. Urol. 2002, 168:1583-1588.
433. Peehl D.M., Seto E., Feldman D. Rationale for combination ketoconazole/vitamin D treatment of prostate cancer. Urology 2001, 58:123-126.
434. Campbell M.J., Drayson M.T., Durham J., Wallington L., Siu-Caldera M.L., Reddy G.S., et al. Metabolism of 1alpha,25(OH)2D3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation. Mol. Cell Endocrinol. 1999, 149:169-183.
435. Johnson C.S., Chung I., Trump D.L. Epigenetic silencing of CYP24 in the tumor microenvironment. J. Steroid Biochem. Mol. Biol. 2010.
436. Quack M., Mork H.C., Binderup E., Kissmeyer A.M., Carlberg C. Metabolism of the vitamin D3 analogue EB1089 alters receptor complex formation and reduces promoter selectivity. Br. J. Pharmacol. 1998, 125:607-614.
437. Dilworth F.J., Williams G.R., Kissmeyer A.M., Nielsen J.L., Binderup E., Calverley M.J., et al. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 1997, 138:5485-5496.
438. van den Bemd G.C., Dilworth F.J., Makin H.L., Prahl J.M., DeLuca H.F., Jones G., et al. Contribution of several metabolites of the vitamin D analog 20-epi-22-oxa-24a,26a,27a-tri-homo-1,25-(OH)(2) vitamin D(3) (KH 1060) to the overall biological activity of KH1060 by a shared mechanism of action. Biochem. Pharmacol. 2000, 59:621-627.
439. Taniyama T., Wanibuchi H., Salim E.I., Yano Y., Otani S., Nishizawa Y., et al. Chemopreventive effect of 24R,25-dihydroxyvitamin D(3) in N, N'-dimethylhydrazine-induced rat colon carcinogenesis. Carcinogenesis 2000, 21:173-178.
440. Farhan H., Wahala K., Cross H.S. Genistein inhibits Vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. Biol. 2003, 84:423-429.
441. Swami S., Krishnan A.V., Peehl D.M., Feldman D. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol. Cell Endocrinol. 2005, 241:49-61.
442. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 2000, 25:144-146.
443. Cross H.S., Bareis P., Hofer H., Bischof M.G., Bajna E., Kriwanek S., et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66:287-292.
444. Bareis P., Kallay E., Bischof M.G., Bises G., Hofer H., Potzi C., et al. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3). Exp. Cell Res. 2002, 276:320-327.
445. Holt P.R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K.A., et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol. Biomarkers Prev. 2002, 11:113-119.
446. Chen T.C., Wang L., Whitlatch L.W., Flanagan J.N., Holick M.F. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell Biochem. 2003, 88:315-322.
447. Ogose A., Kawashima H., Morita O., Hotta T., Umezu H., Endo N. Increase in serum 1,25-dihydroxyvitamin D and hypercalcaemia in a patient with inflammatory myofibroblastic tumour. J. Clin Pathol. 2003, 56:310-312.
448. Baier R., Grauer A., Lazaretti-Castro M., Ziegler R., Raue F. Differential effects of 1,25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression. Endocrinology 1994, 135:2006-2011.
449. Ohta M., Okabe T., Ozawa K., Urabe A., Takaku F. 1 Alpha,25-dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett. 1985, 185:9-13.
450. Mitsuhashi T., Morris R.C., Ives H.E. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J. Clin. Invest. 1991, 87:1889-1895.
451. Edelson J.D., Chan S., Jassal D., Post M., Tanswell A.K. Vitamin D stimulates DNA synthesis in alveolar type-II cells. Biochim. Biophys. Acta. 1994, 1221:159-166.
452. Lutzow-Holm C., De Angelis P., Grosvik H., Clausen O.P. 1,25-Dihydroxyvitamin D3 and the vitamin D analogue KH1060 induce hyperproliferation in normal mouse epidermis. A BrdUrd/DNA flow cytometric study. Exp. Dermatol. 1993, 2:113-120.
453. Gniadecki R. A vitamin D analogue KH 1060 activates the protein kinase C-c-fos signalling pathway to stimulate epidermal proliferation in murine skin. J. Endocrinol. 1994, 143:521-525.
454. Gniadecki R., Serup J. Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogues of 1 alpha, 25-dihydroxyvitamin D3. Biochem. Pharmacol. 1995, 49:621-624.
455. Gniadecki R., Gniadecka M., Serup J. The effects of KH 1060, a potent 20-epi analogue of the vitamin D3 hormone, on hairless mouse skin in vivo. Br. J. Dermatol. 1995, 132:841-852.
456. Hosoi J., Abe E., Suda T., Colburn N.H., Kuroki T. Induction of anchorage-independent growth of JB6 mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 1986, 46:5582-5586.
457. Kitano Y., Ikeda N., Okano M. Suppression of proliferation of human epidermal keratinocytes by 1,25-dihydroxyvitamin D3. Analysis of its effect on psoriatic lesion and of its mechanism using human keratinocytes in culture. Eur. J. Clin. Invest. 1991, 21:53-58.
458. Hosomi J., Hosoi J., Abe E., Suda T., Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology 1983, 113:1950-1957.
459. Kragballe K. Vitamin D3 and skin diseases. Arch. Dermatol. Res. 1992, 284(Suppl. 1):S30-S36.
460. Kuroki T., Sasaki K., Chida K., Abe E., Suda T. 1 Alpha,25-dihydroxyvitamin D3 markedly enhances chemically-induced transformation in BALB 3T3 cells. Gann. 1983, 74:611-614.
461. Sasaki K., Chida K., Hashiba H., Kamata N., Abe E., Suda T., et al. Enhancement by 1 alpha,25-dihydroxyvitamin D3 of chemically induced transformation of BALB 3T3 cells without induction of ornithine decarboxylase or activation of protein kinase C1. Cancer Res. 1986, 46:604-610.
462. Jones C.A., Callaham M.F., Huberman E. Enhancement of chemical-carcinogen-induced cell transformation in hamster embryo cells by 1 alpha,25-dihydroxycholecalciferol, the biologically active metabolite of vitamin D3. Carcinogenesis 1984, 5:1155-1159.
463. Wood A.W., Chang R.L., Huang M.T., Baggiolini E., Partridge J.J., Uskokovic M., et al. Stimulatory effect of 1 alpha, 25-dihydroxyvitamin D3 on the formation of skin tumors in mice treated chronically with 7,12-dimethylbenz[a]anthracene. Biochem. Biophys. Res. Commun. 1985, 130:924-931.
464. Chang P.L., Prince C.W. 1 Alpha,25-dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate-induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells. Cancer Res. 1993, 53:2217-2220.
465. Chang P.L., Lee T.F., Garretson K., Prince C.W. Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathways. Clin Exp. Metastasis 1997, 15:580-592.
466. Yamaoka K., Marion S.L., Gallegos A., Haussler M.R. 1,25-Dihydroxyvitamin D3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells. Biochem. Biophys. Res. Commun. 1986, 139:1292-1298.
467. Franceschi R.T., James W.M., Zerlauth G. 1 Alpha, 25-dihydroxyvitamin D3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. J. Cell Physiol. 1985, 123:401-409.
468. Gronowicz G., Egan J.J., Rodan G.A. The effect of 1,25-dihydroxyvitamin D3 on the cytoskeleton of rat calvaria and rat osteosarcoma (ROS 17/2.8) osteoblastic cells. J. Bone Miner. Res. 1986, 1:441-455.
469. Hodge B.O., Kream B.E. Variable effects of dexamethasone on protein synthesis in clonal rat osteosarcoma cells. Endocrinology 1988, 122:2127-2133.
470. Abbadia Z., Amiral J., Trzeciak M.C., Delmas P.D., Clezardin P. The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. FEBS Lett. 1993, 335:161-166.
471. Huerta S., Irwin R.W., Heber D., Go V.L., Moatamed F., Ou C., et al. Intestinal polyp formation in the Apcmin mouse: effects of levels of dietary calcium and altered vitamin D homeostasis. Dig. Dis. Sci. 2003, 48:870-876.
472. Young M.R., Halpin J., Wang J., Wright M.A., Matthews J., Pak A.S. 1 Alpha,25-dihydroxyvitamin D3 plus gamma-interferon blocks lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immunosuppressor cells. Cancer Res. 1993, 53:6006-6010.
473. Sahpazidou D., Stravoravdi P., Toliou T., Geromichalos G., Zafiriou G., Natsis K., et al. Significant experimental decrease of the hepatocellular carcinoma incidence in C3H/Sy mice after long-term administration of EB1089, a vitamin D analogue. Oncol. Res. 2003, 13:261-268.